Is ibogaine legal in the United States?
No. Ibogaine is a Schedule I controlled substance under the federal Controlled Substances Act (21 U.S.C. § 812) — the federal government has determined it has no currently accepted medical use, a high potential for abuse, and lacks accepted safety for use under medical supervision. There is no FDA-approved ibogaine product, and no state has legalized ibogaine for personal use or clinical treatment in the sources reviewed on November 14, 2026.
What has changed is state-level research funding and process, not legal status. The Texas Health and Human Services Commission says Senate Bill 2308 directed it to request consortium proposals for ibogaine drug development clinical trials, selected UTHealth Houston as lead institution, and says recent plans submitted to it do not meet Chapter 491 requirements. That is state research funding and process rather than a change to ibogaine's legal status in the sources reviewed on November 14, 2026, and the Texas SB 2308 guide covers the statute's background. Arizona passed HB 2871, appropriating $5 million for ibogaine neuroscience research — see the Arizona HB 2871 guide. Kentucky saw legislative interest in 2024 that was ultimately not funded; no bill passed. None of these programs changes ibogaine’s federal Schedule I status, so a resident of Texas or Arizona has the same federal status as a resident of any other state.
FDA's Request for Information on Ibogaine Trials
The Food and Drug Administration (FDA) published a request for information (RFI) regarding early-phase clinical trial designs for ibogaine drug products, but the notice is not an approval of any ibogaine product, and the sources reviewed say nothing that changes ibogaine's Schedule I status. Published under Docket No. FDA-2026-N-10429 on regulations.gov, the FDA press announcement sets a comment period that closes Friday, November 20, 2026. The action represents the agency's latest step to advance an April 2026 executive order by President Trump directing federal agencies to accelerate research into psychedelic medicine.
Regulators are seeking public input across four defined areas: general study design, dose selection and escalation, safety considerations, and ethical oversight. On dosing, the agency asks for comment on a proposed use of small, sequential dose-ascending groups with a starting dose justified by available data and not exceeding 10 mg/kg. The request also solicits data on appropriate patient populations, cardiac and neurologic adverse event monitoring, care settings, stopping rules, informed consent, and independent safety oversight.
Center for Drug Evaluation and Research (CDER) Director Michael Davis, M.D., Ph.D., is quoted saying that with ibogaine, there are important scientific questions as well as serious safety concerns. In July 2026, the agency issued finalized guidance titled Psychedelic Drugs: Considerations for Clinical Investigations. The FDA has also allowed an early-phase clinical study of noribogaine hydrochloride, a derivative of ibogaine, to proceed under an Investigational New Drug (IND) application. Late comments on the RFI will not be considered.
The Advanced Research Projects Agency for Health (ARPA-H), an agency within the Department of Health and Human Services (HHS), announced awards on November 12, 2026 of up to $4.9 million over five years to two teams for groundwork toward future Investigational New Drug (IND) applications. ARPA-H said on November 12, 2026 that "no current IND exists to legally and safely conduct clinical research on ibogaine as a treatment for psychiatric conditions in the United States." In its October 5, 2026 release, the FDA said it had allowed an early-phase study of noribogaine hydrochloride, an ibogaine derivative, to proceed under an IND for alcohol use disorder. The same FDA release said the National Institute on Drug Abuse (NIDA) is funding research on ibogaine for opioid use disorder (OUD), and HHS is prioritizing adults with OUD and adults with post-traumatic stress disorder (PTSD) for federally supported research. In the sources reviewed on November 14, 2026, the awards are not an approval and do not change ibogaine's Schedule I listing under 21 CFR 1308.11. See what the awards fund and do not authorize.
US state-level ibogaine activity
| Jurisdiction | Status | Details |
|---|---|---|
| Federal (all states) | Schedule I | Ibogaine has no accepted medical use under federal law, and no FDA approval of ibogaine appears in the sources reviewed on November 14, 2026. No state can override federal scheduling. |
| Texas | Research process (SB 2308) | Texas HHSC says it selected UTHealth Houston as lead institution for the Senate Bill 2308 trials and that recent plans do not meet Chapter 491 requirements, and it lists no trial start date (read November 14, 2026). Does not legalize possession. |
| Arizona | Research funding (HB 2871) | $5 million appropriated for ibogaine neuroscience research. Does not create a treatment-access pathway outside authorized research. |
| Kentucky | No bill passed | 2024 legislative interest in ibogaine research funding was ultimately not funded. Ibogaine remains Schedule I in Kentucky with no state research program. |
| Oregon & Colorado | Schedule I | A common point of confusion: Oregon’s Measure 109 (2020) and Colorado’s Prop 122 / Natural Medicine Health Act (2022) created regulated legal-access frameworks for psilocybin specifically — neither program names or covers ibogaine. Ibogaine remains a Schedule I controlled substance in both states with no licensed access pathway. |
| All other states | Schedule I | Ibogaine is a Schedule I controlled substance with no state-level research funding or access program in the sources reviewed on November 14, 2026. |
International ibogaine legal status
The countries below are the ones with a documented, sourced legal position on ibogaine. This is not an exhaustive list of every country in the world — it is limited to jurisdictions where we can point to a specific law, regulatory decision, or scheduling status.
| Country | Status | Details |
|---|---|---|
| Costa Rica | Uncontrolled | Ibogaine and iboga alkaloids are not listed on the controlled substance schedules of Costa Rica’s Ley sobre Estupefacientes (Law No. 8204), so operating an ibogaine clinic is legal. Uncontrolled does not mean regulated. There is no government oversight of clinic quality or safety protocols. Full detail: Costa Rica ibogaine legal guide. |
| Canada | Schedule III — research only | Ibogaine is a Schedule III controlled substance under Canada’s Controlled Drugs and Substances Act. Health Canada has not approved it as a therapeutic product under the Food and Drugs Act, so it cannot be legally manufactured, sold, or marketed for treatment. The Act’s Section 56 exemption power lets the Minister authorize a controlled substance for medical or scientific purposes on a case-by-case basis, and this is the mechanism Canadian institutions use to access ibogaine for research — it is not a general legal-access pathway, and no commercial ibogaine clinic operates lawfully in Canada under it. |
| United States | Schedule I | No accepted medical use federally. Texas and Arizona fund research (not access); Kentucky’s 2024 funding effort did not pass. See full detail above. |
Can I bring ibogaine back to the United States?
No. Ibogaine remains Schedule I under US federal law regardless of its status in any other country. Importing it into the United States is regulated under the Controlled Substances Import and Export Act (21 U.S.C. 951 and following); consult a licensed attorney. US health insurance — including Medicare, Medicaid, and VA benefits — does not cover ibogaine treatment abroad.